Physician profile
Chris M Oneil
NPI 1154313450
$10,778.41
in general payments reported to CMS, 2019-2025
44 companies · $1,806 in 2025
The $1,806 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $940 · 2020: $913 · 2021: $1,607 · 2022: $2,076 · 2023: $1,793 · 2024: $1,643 · 2025: $1,806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,226 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,226.01 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,877.34 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,471.40 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,113.07 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $858.44 | 2019-2025 | |
| Amgen INC. | $763.62 | 2019-2025 | Otezla, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $676.81 | 2019-2025 | Tradjenta, Jardiance, Synjardy |
| Lilly USA, LLC | $670.88 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $453.45 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $394.25 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Bayer Healthcare Pharmaceuticals INC. | $308.22 | 2022-2025 | |
| Glaxosmithkline, LLC. | $230.58 | 2019-2025 | Arexvy, Trelegy Ellipta, Bexsero |
| Exact Sciences Corporation | $224.62 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $150.50 | 2020-2023 | Spravato |
| Sanofi-Aventis U.S. LLC | $147.66 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $145.84 | 2019-2024 | Eliquis |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chris Oneil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.